Onderzoeksoutput

Onderzoeksoutput per jaar 2016 2016 2019 2020 2022 2023 2024 2024

• 134 Citaties
• 6 h-index
• 10 Article
• 4 Meeting abstract (Journal)
• 2 Unpublished abstract
• 1 Poster
• 1 Meer
  • 1 PhD Thesis

Onderzoeksoutput per jaar

Onderzoeksoutput per jaar

Zoekresultaten

• 2024

  Identification of RAD17 as a candidate cancer predisposition gene in families with histories of pancreatic and breast cancers

  Joris, S., Giron, P., Olsen, C., Seneca, S., Gheldof, A., Staessens, S., Shahi, R. B., De Brakeleer, S., Teugels, E., De Grève, J. & Hes, F. J., 13 jun 2024, In: BMC Cancer. 24, 1, 9 blz., 723.

  Onderzoeksoutput: Article › peer review

  Open Access

  • Neoplasm Genes 100%
  • Pancreatic Neoplasms 87%
  • Breast Neoplasms 58%
  • DNA Repair 36%
  • DNA Damage 34%

• Phase II Trial Assessing the Repeatability and Tumor Uptake of [68Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma

  Gondry, O., Caveliers, V., Xavier, C., Vanhoeij, M., Verfaillie, G., Fontaine, C., Glorieus, K., De Grève, J., Joris, S., Luyten, I., Zwaenepoel, K., Vandenbroucke, F., Waelput, W., Thyparambil, S., Vaneycken, I., Cousaert, J., Bourgeois, S., Devoogdt, N., Goethals, L., Everaert, H. & 4 anderen, De Geeter, F., Lahoutte, T., Keyaerts, M. & Raes, L., 1 feb 2024, In: Journal of Nuclear Medicine. 65, 2, blz. 178-184 7 blz.

  Onderzoeksoutput: Article › peer review

  Open Access

  Bestand

  • Single-Domain Antibodies 100%
  • human ERBB2 protein 82%
  • 1,4,7-triazacyclononane-N,N',N''-triacetic acid 49%
  • Breast Neoplasms 43%
  • Fluorodeoxyglucose F18 25%
  6 Citaten (Scopus)

  41 Downloads (Pure)

• Realizing the power of cancer genetics

  Joris, S., 2024, 108 blz.

  Onderzoeksoutput: PhD Thesis

  • Psychological Power 100%
  • Pancreatic Neoplasms 93%
  • Breast Neoplasms 58%
  • Neoplasm Genes 45%
  • Neoplasms 34%
• 2023

  A comparison of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT with [18F]FDG-PET/CT in breast carcinoma patients.

  Gondry, O., Xavier, C., Heemskerk, J., Raes, L. A. J., Debacker, J., De Geeter, F., Fontaine, C., Vanhoeij, M., Aspeslagh, S., Joris, S., De Grève, J., Verfaillie, G., Luyten, I., De Mey, L., Vandenbroucke, F., Waelput, W., Glorieus, K., Bourgeois, S., Cousaert, J., Vaneycken, I. & 5 anderen, Devoogdt, N., Everaert, H., Caveliers, V., Lahoutte, T. & Keyaerts, M., 2023.

  Onderzoeksoutput: Unpublished abstract

  • breast neoplasms 100%
  • tracer techniques 75%
  • antibodies 57%
  • uptake mechanisms 50%
  • repeatability 34%

• Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study

  Joris, S., Denys, H., Collignon, J., Rasschaert, M., T'Kint de Roodenbeke, D., Duhoux, F. P., Canon, J-L., Tejpar, S., Mebis, J., Decoster, L., Aftimos, P. & De Grève, J., dec 2023, In: ESMO Open. 8, 6, 8 blz., 102041.

  Onderzoeksoutput: Article › peer review

  Open Access

  Bestand

  • olaparib 100%
  • Germ-Line Mutation 73%
  • Mutation 36%
  • Neoplasms 20%
  • Gallbladder Neoplasms 19%
  8 Citaten (Scopus)

  15 Downloads (Pure)
• 2022

  Assessment of repeatability and uptake quantification of (68)GaNOTA-anti-HER2 sdAb PET/CT in patients with locally advanced or metastatic breast cancer

  Gondry, O., Xavier, C., Waelput, W., Al Dabssi, O., Vanhoeij, M., Aspeslagh, S., Joris, S., Fontaine, C., Verfaillie, G., De Greve, J., Glorieus, K., Luyten, I., Vandenbroucke, F., Bourgeois, S., Thyparambil, S., Devoogdt, N., Vaneycken, I., Cousaert, J., Caveliers, V., Everaert, H. & 3 anderen, Lahoutte, T., Keyaerts, M. & Raes, L. A. J., 15 feb 2022, In: Cancer Research. 82, 4, blz. P3-02-05

  Onderzoeksoutput: Meeting abstract (Journal)

  Open Access

  • Single-Domain Antibodies 100%
  • human ERBB2 protein 82%
  • Breast Neoplasms 43%
  • Fluorodeoxyglucose F18 9%
  • Injections 8%

• Efficacy of a Flat Low Dose of Nivolumab in Advanced Cancer: A Retrospective Case Series

  Joris, S., Fontaine, C., Decoster, L., Vanderauwera, J., Thielemans, K., Waelput, W. & DE-Grève, J., mrt 2022, In: Anticancer Research. 42, 3, blz. 1433-1437 5 blz.

  Onderzoeksoutput: Article › peer review

  Open Access

  Bestand

  • Nivolumab 100%
  • Neoplasms 23%
  • Drug Costs 17%
  • Blocking Antibodies 17%
  • Standard of Care 14%
  5 Citaten (Scopus)

  28 Downloads (Pure)

• PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment

  Thouvenin, J., Van Marcke, C., Decoster, L., Raicevic, G., Punie, K., Vandenbulcke, M., Salgado, R., Van Valckenborgh, E., Maes, B., Joris, S., Steichel, D. V., Vranken, K., Jacobs, S., Dedeurwaerdere, F., Martens, G., Devos, H., Duhoux, F. P., Rasschaert, M., Pauwels, P., Geboes, K. & 23 anderen, Collignon, J., Tejpar, S., Canon, J-L., Peeters, M., Rutten, A., Van de Mooter, T., Vermeij, J., Schrijvers, D., Demey, W., Lybaert, W., Van Huysse, J., Mebis, J., Awada, A., Claes, K. B. M., Hebrant, A., Van der Meulen, J., Delafontaine, B., Bempt, I. V., Maetens, J., de Hemptinne, M., Rottey, S., Aftimos, P. & De Grève, J., aug 2022, In: ESMO Open. 7, 4, 8 blz., 100524.

  Onderzoeksoutput: Article › peer review

  Open Access

  Bestand

  • Neoplasms 100%
  • Medical Oncology 73%
  • Belgium 71%
  • Pharmaceutical Preparations 51%
  • Therapeutics 50%
  4 Citaten (Scopus)

  31 Downloads (Pure)

• Repeatability of 68GaNOTA-anti-HER2 sdAb in 20 breast cancer patients.

  Gondry, O., Xavier, C., De Geeter, F., Al dabssi, O., Glorieus, K., Aspeslagh, S., Joris, S., Fontaine, C., Verfaillie, G., De Grève, J., Vanhoeij, M., Luyten, I., Heemskerk, J., Bourgeois, S., Raes, L. A. J., Devoogdt, N., Vaneycken, I., Cousaert, J., Caveliers, V., Everaert, H. & 2 anderen, Lahoutte, T. & Keyaerts, M., mrt 2022.

  Onderzoeksoutput: Unpublished abstract

  • Single-Domain Antibodies 100%
  • human ERBB2 protein 82%
  • Breast Neoplasms 43%
  • Injections 12%
  • 1,4,7-triazacyclononane-N,N',N''-triacetic acid 12%
• 2021

  Efficacy of olaparib in advanced cancers occurring in patients with germline or somatic tumor mutations in homologous recombination (HR) genes, a Belgian Precision phase II basket study

  Joris, S., Denys, H., Martin, M., t'Kint de Roodenbeke, D., Duhoux, F. P., Berchem, G., Punie, K., Bols, A., Mebis, J., Canon, J-L., Decoster, L. & De Grève, J., 1 sep 2021, In: Annals of Oncology. blz. S394-S394

  Onderzoeksoutput: Meeting abstract (Journal)

  Open Access

  Bestand

  • olaparib 100%
  • Homologous Recombination 73%
  • Mutation 36%
  • Genes 26%
  • Neoplasms 20%
  5 Downloads (Pure)
• 2020

  68GaNOTA-anti-MMR-Nb for PET/CT assessment of protumorigenic macrophages in patients with solid tumors: preliminary results of a phase I clinical trial

  Gondry, O., Xavier, C., Heemskerk, J., Devoogdt, N., Everaert, H., Breckpot, K., Decoster, L., Fontaine, C., Neyns, B., Schallier, D., Joris, S., Aspeslagh, S., Vaneycken, I., Movahedi, K., Raes, G., Van Ginderachter, J., Lahoutte, T., Caveliers, V. & Keyaerts, M., 25 aug 2020.

  Onderzoeksoutput: Poster

  Open Access

  Bestand

  • Single-Domain Antibodies 100%
  • mannose receptor 96%
  • Clinical Trials, Phase I 81%
  • Macrophages 47%
  • Injections 25%
  15 Downloads (Pure)

• Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program

  Joris, S. R., Pieters, T., Sibille, A., Bustin, F., Jacqmin, L., Kalantari, HR., SURMONT, VEERLE., Goeminne, J-C., Clinckart, F., Pat, K., Demey, W., Deschepper, K., Lambrechts, M., Holbrechts, S., Schallier, D. & Decoster, L., jun 2020, In: J Geriatr Oncol. 11, 5, blz. 796-801 6 blz.

  Onderzoeksoutput: Article › peer review

  Open Access

  Bestand

  • Compassionate Use Trials 100%
  • Nivolumab 89%
  • Non-Small Cell Lung Carcinoma 58%
  • Safety 38%
  • Progression-Free Survival 14%
  9 Citaten (Scopus)

  12 Downloads (Pure)
• 2019

  Germ line gene panel analysis in a HBOC population

  Seneca, S., De Greve, J., Bonduelle, M., Joris, S., Keymolen, K., De Rademaeker, M., Stouffs, K. & Gheldof, A., jul 2019, In: European Journal of Human Genetics. 27, blz. 406-406 1 blz.

  Onderzoeksoutput: Meeting abstract (Journal)

• Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families

  Shahi, R. B., De Brakeleer, S., Caljon, B., Pauwels, I., Bonduelle, M., Joris, S., Fontaine, C., Vanhoeij, M., Van Dooren, S., Teugels, E. & De Grève, J., 4 apr 2019, In: BMC Cancer. 19, 1, 11 blz., 313.

  Onderzoeksoutput: Article › peer review

  Open Access

  • Whole Exome Sequencing 100%
  • Breast Neoplasms 53%
  • Neoplasms 27%
  • Neoplasm Genes 26%
  • Familial Breast Cancer 25%
  30 Citaten (Scopus)

• Retrospective comparison of two consecutive cohorts of adjuvant chemotherapy regimens of cyclophosphamide with either docetaxel or paclitaxel in older patients with early breast cancer.

  Joris, S., Fontaine, C., Decoster, L., Vanacker, L., Schallier, D. & De Grève, J., 9 mei 2019, In: The Breast Journal. 25, 4, blz. 663-666 4 blz.

  Onderzoeksoutput: Article › peer review

  Open Access

  Bestand

  • Docetaxel 100%
  • Adjuvant Chemotherapy 90%
  • Paclitaxel 90%
  • Cyclophosphamide 83%
  • Breast Neoplasms 57%
  6 Downloads (Pure)

• The clinical characteristics of breast cancers with a familial risk in which no BRCA1/2 mutations were found are sometimes suggestive for a genetic etiology

  Joris, S., Shahi, R. B., De Brakeleer, S., Fontaine, C., Bonduelle, M-L., Ingrid, P., Teugels, E. & De Grève, J., 15 mei 2019, In: Journal of molecular and genetic medicine. 13, 2, 7 blz., 423.

  Onderzoeksoutput: Article › peer review

  Open Access

  • Breast Neoplasms 100%
  • Mutation 87%
  • Genetic Testing 26%
  • Incidence 25%
  • Neoplasms 25%
• 2016

  Adjuvant chemotherapy with 3-weekly cyclophosphamide and dose dense paclitaxel in early breast cancer patients older than 65 years, a retrospective study

  Fontaine, C., Joris, S., Decoster, L., Vanacker, L., Schallier, D., Vanhoeij, M., Verfaillie, G., Lamote, J. & De Greve, J., apr 2016, In: European Journal of Cancer. 57, blz. S102-S103 2 blz.

  Onderzoeksoutput: Meeting abstract (Journal)

  53 Citaten (Scopus)

• Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients

  De Brakeleer, S., De Grève, J., Desmedt, C., Joris, S., Sotiriou, C., Piccart, M., Pauwels, I. & Teugels, E., mrt 2016, In: Clinical Genetics. 89, 3, blz. 336-340

  Onderzoeksoutput: Article › peer review

  • Triple Negative Breast Neoplasms 100%
  • Germ-Line Mutation 93%
  • Mutation 46%
  • DNA 46%
  • Incidence 40%
  19 Citaten (Scopus)